Profile data is unavailable for this security.
About the company
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
- Revenue in USD (TTM)2.82bn
- Net income in USD-1.87bn
- Incorporated2021
- Employees7.10k
- LocationQuidelOrtho Corp9975 Summers Ridge RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 552-1100
- Fax+1 (858) 453-4338
- Websitehttps://www.quidelortho.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rxsight Inc | 128.29m | -30.69m | 1.82bn | 374.00 | -- | 6.54 | -- | 14.15 | -0.8194 | -0.8194 | 3.40 | 6.89 | 0.5212 | 1.99 | 6.32 | 343,029.40 | -12.47 | -- | -13.62 | -- | 68.44 | -- | -23.92 | -- | 11.71 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Novocure Ltd | 577.74m | -149.78m | 1.85bn | 1.45k | -- | 5.12 | -- | 3.20 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Tandem Diabetes Care Inc | 854.35m | -126.78m | 2.02bn | 2.40k | -- | 8.49 | -- | 2.36 | -1.94 | -1.94 | 13.08 | 3.62 | 0.9004 | 2.90 | 8.23 | 355,979.60 | -13.36 | -10.08 | -17.47 | -12.23 | 49.79 | 51.77 | -14.84 | -11.59 | 2.32 | -- | 0.5945 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Omnicell Inc | 1.06bn | -17.69m | 2.03bn | 3.66k | -- | 1.66 | 30.57 | 1.91 | -0.3917 | -0.3917 | 23.17 | 26.59 | 0.4704 | 5.90 | 4.06 | 291,563.30 | -0.7817 | 1.73 | -1.11 | 2.25 | 41.44 | 46.69 | -1.66 | 2.92 | 0.9529 | -- | 0.3172 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Premier Inc | 1.28bn | 147.17m | 2.15bn | 2.90k | 16.23 | 1.12 | 8.21 | 1.69 | 1.38 | 1.37 | 11.65 | 19.98 | 0.3562 | -- | 2.99 | 439,914.10 | 3.83 | 7.08 | 4.78 | 8.95 | 67.24 | 61.29 | 10.76 | 16.05 | -- | -- | 0.2771 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Conmed Corp | 1.29bn | 131.74m | 2.22bn | 4.00k | 16.96 | 2.37 | 10.88 | 1.72 | 4.23 | 4.23 | 41.38 | 30.21 | 0.555 | 1.71 | 5.58 | 322,029.00 | 5.68 | 0.8972 | 6.62 | 1.02 | 55.65 | 54.95 | 10.23 | 1.65 | 1.06 | 5.22 | 0.5021 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Irhythm Technologies Inc | 560.03m | -150.66m | 2.31bn | 2.00k | -- | 32.22 | -- | 4.13 | -4.85 | -4.85 | 18.04 | 2.29 | 0.83 | 12.56 | 8.79 | 280,012.50 | -22.33 | -21.92 | -26.27 | -26.77 | 67.83 | 69.39 | -26.90 | -25.75 | 6.12 | -24.18 | 0.90 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| UFP Technologies Inc | 461.85m | 54.21m | 2.34bn | 3.09k | 43.55 | 7.11 | 34.79 | 5.06 | 7.00 | 7.00 | 59.64 | 42.89 | 0.8896 | 4.18 | 6.15 | 149,320.40 | 10.44 | 9.69 | 12.00 | 10.95 | 28.31 | 26.33 | 11.74 | 10.14 | 1.43 | 13.44 | 0.3919 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LeMaitre Vascular Inc | 213.03m | 41.32m | 2.38bn | 614.00 | 58.07 | 7.19 | 46.72 | 11.17 | 1.82 | 1.82 | 9.41 | 14.73 | 0.5992 | 1.11 | 7.59 | 346,952.80 | 11.62 | 9.02 | 12.66 | 9.93 | 68.34 | 65.83 | 19.40 | 15.45 | 5.52 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Quidelortho Corp | 2.82bn | -1.87bn | 2.55bn | 7.10k | -- | 0.799 | -- | 0.9044 | -27.89 | -27.89 | 42.04 | 47.42 | 0.3674 | 2.62 | 7.84 | 396,859.20 | -24.34 | 11.34 | -27.75 | 12.91 | 47.62 | 62.71 | -66.25 | 20.93 | 0.8134 | 0.7419 | 0.4446 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| Enovis Corp | 2.00bn | -121.38m | 2.58bn | 6.55k | -- | 0.7745 | 17.63 | 1.29 | -2.21 | -2.17 | 36.43 | 59.61 | 0.4023 | 1.59 | 5.91 | 305,598.20 | -2.43 | -0.3569 | -2.66 | -0.41 | 56.96 | 48.19 | -6.03 | -1.06 | 1.12 | 0.9889 | 0.2876 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| TransMedics Group Inc | 401.09m | 32.64m | 2.66bn | 584.00 | 84.50 | 12.68 | 52.79 | 6.64 | 0.9389 | 0.9389 | 11.60 | 6.25 | 0.5439 | 3.56 | 5.32 | 686,797.90 | 4.43 | -16.08 | 4.78 | -17.95 | 59.34 | 65.37 | 8.14 | -40.47 | 7.33 | -- | 0.7078 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| Warby Parker Inc | 742.53m | -32.56m | 2.80bn | 2.14k | -- | 8.31 | 246.87 | 3.77 | -0.2731 | -0.2731 | 6.20 | 2.80 | 1.22 | 5.70 | 818.21 | 346,975.20 | -5.37 | -- | -6.78 | -- | 55.32 | 57.49 | -4.39 | -14.53 | 2.06 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| LivaNova PLC | 1.24bn | 23.68m | 2.81bn | 2.90k | 121.38 | 2.14 | 41.37 | 2.26 | 0.4259 | 0.4259 | 22.81 | 24.13 | 0.5119 | 2.47 | 6.42 | 428,185.90 | 0.9777 | -6.01 | 1.12 | -7.42 | 67.78 | 66.99 | 1.91 | -13.56 | 2.87 | 2.46 | 0.3234 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Inari Medical Inc | 574.50m | -78.58m | 2.91bn | 1.30k | -- | 6.69 | -- | 5.07 | -1.35 | -1.35 | 9.90 | 7.44 | 0.9221 | 1.59 | 7.46 | 441,921.50 | -12.61 | -0.5941 | -15.24 | -0.6696 | 86.82 | 89.06 | -13.68 | -0.6295 | 1.40 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| Neogen Corp | 912.20m | -23.53m | 3.16bn | 2.92k | -- | 1.01 | 33.52 | 3.46 | -0.1086 | -0.1086 | 4.21 | 14.47 | 0.2013 | 2.71 | 5.98 | 312,718.20 | -0.5193 | 1.38 | -0.5346 | 1.44 | 49.56 | 48.23 | -2.58 | 4.31 | 2.79 | 1.03 | 0.2215 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
Data as of Nov 22 2024. Currency figures normalised to QuidelOrtho Corp's reporting currency: US Dollar USD
53.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 9.40m | 13.98% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.70m | 9.96% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.96m | 8.87% |
| Rubric Capital Management LPas of 30 Sep 2024 | 4.20m | 6.25% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.91m | 2.84% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2024 | 1.88m | 2.79% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 1.74m | 2.59% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 1.68m | 2.50% |
| Maverick Capital Ltd.as of 30 Sep 2024 | 1.61m | 2.40% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 1.22m | 1.81% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
